Stockreport

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

Supernus Pharmaceuticals, Inc.  (SUPN) 
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.supernus.com
PDF Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptoms Suicidal ideation decreased by 80% SPN-820 was well-tolerated with [Read more]